ClinicalTrials.Veeva

Menu

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Adult Growth Hormone Deficiency
Growth Hormone Disorder

Treatments

Drug: somatropin

Study type

Observational

Funder types

Industry

Identifiers

NCT01109017
GH-3811
U1111-1114-6250 (Other Identifier)
JapicCTI-101122 (Registry Identifier)

Details and patient eligibility

About

This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® long-term treatment of growth hormone deficiency in adults.

Enrollment

387 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Severe adult growth hormone deficiency

Exclusion criteria

  • Known or suspected allergy to study product(s) or related products
  • Previous participation in the study
  • Diabetes Mellitus
  • Presence of malignant tumor(s)
  • Pregnant or likely to get pregnant

Trial design

387 participants in 1 patient group

Norditropin®
Treatment:
Drug: somatropin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems